Los objetivos de las guías son brindar directrices para optimizar el cuidado de la mayoría de los pacientes afectados por los VHB y VHC. Sin embargo, no reemplazan el criterio médico en la valoración y abordaje del paciente individual. En situaciones especiales, el mejor enfoque en el diagnóst...ico y tratamiento puede diferir de la presente guía, y deben basarse en el análisis del caso individual
por expertos en el área.
more
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...h disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
The path to elimination provides a framework with 3 levels of achievements for which WHO certification is available. Each stepwise progression from bronze to silver to gold tiers will promote an iterative expansion of prevention, diagnosis and treatment services for viral hepatitis services and strengthen measurement systems to support attainment of the 2030 elimination goals.
This updated version also includes changes, clarifications and new guidance on alternative measurement approaches for country validation of elimination. Through the validation process, WHO and partners continue to provide country support for strengthening health system capacity and patient-centred services that respect and protect the human rights of people living with viral hepatitis and ensures meaningful engagement of communities in the national, regional and global viral hepatitis response.
more
Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease.
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment criteria for adults but now also for adolescents; expa...nded eligibility for antiviral prophylaxis for pregnant women to prevent mother-to-child transmission of HBV; improving HBV diagnostics through use of point-of-care HBV DNA viral load and reflex approaches to HBV DNA testing; who to test and how to test for HDV infection; and approaches to promote delivery of high-quality HBV services, including strategies to promote adherence to long-term antiviral therapy and retention in care.
The 2024 guidelines include 11 updated chapters with new recommendations and also update existing chapters without new recommendations, such as those on treatment monitoring and surveillance for liver cancer.
more
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more
J Hepatol (2017), http://dx.doi.org/10.1016/j.jhep.2017.03.021
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Investigación original / Original research
Rev Panam Salud Publica 35(1), 2014
Multiple countries are reporting severe acute cases of hepatitis of unknown aetiology in children, in several
regions of the world. WHO has developed this clinical case report form (CRF) to support and facilitate reporting
of anonymized, patient-level data of acute hepatitis of unknown aetiology.
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnostic stakeholders across Member States and national pu...blic health authorities involved in the identification and investigation of cases of severe acute hepatitis in children.
This document is part of a package of guidance for this event, which includes suggested minimum reporting variables and a clinical Case Report Form support Member States with case investigation and reporting.
more
Policy Brief. 24 June 2022. This policy brief, one of two on the updated hepatitis C (HCV) guidelines, focuses on the new recommendations on simplified service delivery for a public health approach to HCV testing, care and treatment. These recommendations include decentralization, integration and ta...sk-sharing, in addition to the use of point-of-care (POC) HCV viral load assays and reflex viral load testing.
more
The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera...l public.
Les notes de synthèse s’adressent aux responsables nationaux de la santé publique et aux administrateurs des programmes de vaccination, mais elles peuvent également présenter un intérêt pour les organismes internationaux de financement, les groupes consultatifs sur la vaccination, les fabricants de vaccins, les professionnels de la santé, les chercheurs, les médias scientifiques et le grand public.
more
Exciting new treatment approaches make the management of hepatitic C one of the most rapidly developing areas of medicine. The Flying Publisher short Guide to Hepatitis C is an up-to-date source of information for physicians, residents and advanced medical students.
Die Merkblätter können kostenlos in verschiedenen Sprachen (Deutsch, Englisch, Albanisch, Arabisch, Farsi, Paschtunisch, Kurdisch, Serbisch, Somali, Urdu und Tigrinya) heruntergeladen werden auf der Webseite
http://www.lgl.bayern.de/gesundheit/infektionsschutz/asylbewerber_gesundheit/index.htm
u...nter dem Punkt "Asylbewerber und Gesundheit"
more
Information sheet for asylum seekers: Hepatitis B
Die Infoblätter können kostenlos auf der Webseite http://www.lgl.bayern.de/gesundheit/infektionsschutz/asylbewerber_gesundheit/index.htm unter dem Punkt "Asylbewerber und Gesundheit" heruntergeladen werden. Weitere Versionen in folgenden Sprachen dort erhältlich: Arabisch, Bulgarisch, Englisch, ...Französisch, Griechisch, Italienisch, Kroatisch, Polnisch, Rumänisch, Russisch, Serbisch (kyrillische oder lateinische Schrift), Spanisch, Türkisch, Ungarisch.
more
Information leaflets can be downloaded free of charge from http://www.lgl.bayern.de/gesundheit/infektionsschutz/asylbewerber_gesundheit/index.htm under the section "Asylbewerber und Gesundheit". Also available in following language versions: Arabic, Bulgarian, German, French, Greek, Italian, Croati...an, Polish, Romanian, Russian, Serbian (kyrillic or latin), Spanish, Turkish, Hungarian.
more